Jubilant Life Sciences said its wholly-owned subsidiary has received approval from the Australian health regulator Therapeutic Goods Administration (TGA) for Lyophilized kit for preparation of injection used for lungs scan.
“Jubilant Pharma, through one of its units Jubilant DraxImage Inc Montreal Canada (JDI), has received approval from TGA, Australia, for Lyophilized kit for preparation of Technetium 99m Macro-Aggregated Albumin (MAA) injection,” Jubilant Life Sciences said in a BSE filing.
It further said “MAA provides accurate scans to assess lung perfusion and rule out pulmonary embolism with low radiation exposure. JDI is the leading supplier of MAA in the US and has approval in four other countries, including Canada, Columbia, Hong Kong and Israel.”
The Australian MAA product is expected to be launched as part of JDI’s larger commitment to investing in the growth and robust sustainability of Nuclear Medicine globally and cater to the needs of suspected pulmonary embolism patients, the company added.
